Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 249 | 2025 | 348 | 60.330 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 110 | 2025 | 444 | 19.550 |
Why?
|
Antibodies, Monoclonal | 79 | 2025 | 866 | 14.600 |
Why?
|
Dexamethasone | 70 | 2025 | 205 | 9.750 |
Why?
|
Antineoplastic Agents | 36 | 2024 | 660 | 9.410 |
Why?
|
Hematopoietic Stem Cell Transplantation | 38 | 2024 | 348 | 6.550 |
Why?
|
Immunotherapy, Adoptive | 29 | 2025 | 96 | 5.780 |
Why?
|
Neoplasm Recurrence, Local | 45 | 2025 | 334 | 5.390 |
Why?
|
Antineoplastic Agents, Immunological | 15 | 2025 | 46 | 5.330 |
Why?
|
Antibodies, Bispecific | 14 | 2025 | 31 | 4.870 |
Why?
|
B-Cell Maturation Antigen | 18 | 2025 | 20 | 4.640 |
Why?
|
Bortezomib | 32 | 2025 | 56 | 4.320 |
Why?
|
Neoplasm, Residual | 19 | 2025 | 42 | 4.170 |
Why?
|
Humans | 277 | 2025 | 62549 | 3.630 |
Why?
|
Thalidomide | 21 | 2024 | 34 | 3.560 |
Why?
|
Antibodies, Monoclonal, Humanized | 16 | 2025 | 233 | 3.080 |
Why?
|
Aged | 114 | 2025 | 14212 | 2.860 |
Why?
|
Transplantation, Autologous | 32 | 2024 | 125 | 2.610 |
Why?
|
Treatment Outcome | 58 | 2025 | 5558 | 2.420 |
Why?
|
Middle Aged | 103 | 2025 | 17303 | 2.280 |
Why?
|
Recurrence | 28 | 2025 | 630 | 2.250 |
Why?
|
Hematologic Neoplasms | 5 | 2025 | 48 | 2.240 |
Why?
|
Male | 120 | 2025 | 29393 | 2.230 |
Why?
|
Female | 121 | 2025 | 32404 | 2.110 |
Why?
|
Drug Resistance, Neoplasm | 25 | 2024 | 194 | 2.070 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 4 | 2023 | 144 | 2.030 |
Why?
|
Oligopeptides | 15 | 2025 | 133 | 1.990 |
Why?
|
Aged, 80 and over | 50 | 2025 | 5394 | 1.900 |
Why?
|
Adult | 77 | 2025 | 16577 | 1.850 |
Why?
|
Biomarkers, Tumor | 16 | 2025 | 502 | 1.840 |
Why?
|
Plasma Cells | 8 | 2022 | 52 | 1.580 |
Why?
|
Prognosis | 34 | 2025 | 1717 | 1.580 |
Why?
|
Neoplasms, Second Primary | 5 | 2023 | 47 | 1.540 |
Why?
|
Injections, Subcutaneous | 10 | 2022 | 70 | 1.480 |
Why?
|
Chromosome Aberrations | 8 | 2025 | 68 | 1.400 |
Why?
|
T-Lymphocytes | 8 | 2024 | 1004 | 1.380 |
Why?
|
Melphalan | 9 | 2024 | 23 | 1.360 |
Why?
|
ADP-ribosyl Cyclase 1 | 6 | 2023 | 28 | 1.350 |
Why?
|
Clinical Trials as Topic | 10 | 2023 | 452 | 1.310 |
Why?
|
Salvage Therapy | 9 | 2023 | 73 | 1.290 |
Why?
|
Administration, Intravenous | 8 | 2022 | 66 | 1.260 |
Why?
|
Quality of Life | 9 | 2025 | 1217 | 1.230 |
Why?
|
Immunologic Factors | 7 | 2022 | 104 | 1.180 |
Why?
|
Survival Rate | 18 | 2025 | 838 | 1.100 |
Why?
|
Flow Cytometry | 5 | 2022 | 669 | 1.090 |
Why?
|
Practice Guidelines as Topic | 7 | 2024 | 725 | 1.070 |
Why?
|
Retrospective Studies | 32 | 2025 | 6494 | 1.060 |
Why?
|
Cell- and Tissue-Based Therapy | 6 | 2023 | 39 | 1.060 |
Why?
|
Myeloma Proteins | 7 | 2021 | 7 | 1.030 |
Why?
|
Immunoglobulin Light Chains | 4 | 2021 | 16 | 0.990 |
Why?
|
Waldenstrom Macroglobulinemia | 3 | 2023 | 8 | 0.990 |
Why?
|
HSP90 Heat-Shock Proteins | 3 | 2011 | 65 | 0.960 |
Why?
|
Physicians | 4 | 2023 | 464 | 0.950 |
Why?
|
Positron-Emission Tomography | 4 | 2015 | 208 | 0.940 |
Why?
|
Chromosomes, Human, Pair 1 | 4 | 2025 | 23 | 0.920 |
Why?
|
Membrane Glycoproteins | 5 | 2020 | 669 | 0.890 |
Why?
|
Patient Reported Outcome Measures | 5 | 2025 | 139 | 0.830 |
Why?
|
Smoldering Multiple Myeloma | 5 | 2024 | 5 | 0.810 |
Why?
|
Maintenance Chemotherapy | 4 | 2021 | 14 | 0.790 |
Why?
|
CD3 Complex | 1 | 2022 | 65 | 0.780 |
Why?
|
Immunotherapy | 5 | 2024 | 250 | 0.770 |
Why?
|
Injection Site Reaction | 2 | 2021 | 3 | 0.760 |
Why?
|
Disease-Free Survival | 15 | 2022 | 241 | 0.760 |
Why?
|
Health Status Disparities | 1 | 2023 | 143 | 0.750 |
Why?
|
Disease Progression | 15 | 2024 | 1159 | 0.720 |
Why?
|
Sulfides | 2 | 2020 | 22 | 0.720 |
Why?
|
Acetates | 2 | 2020 | 32 | 0.710 |
Why?
|
Quinolines | 2 | 2020 | 42 | 0.710 |
Why?
|
Cyclopropanes | 2 | 2020 | 49 | 0.710 |
Why?
|
Proteasome Inhibitors | 10 | 2023 | 30 | 0.710 |
Why?
|
Immunoconjugates | 2 | 2024 | 89 | 0.700 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2021 | 93 | 0.690 |
Why?
|
Transplantation Conditioning | 5 | 2019 | 102 | 0.690 |
Why?
|
Amyloidosis | 3 | 2016 | 63 | 0.690 |
Why?
|
Cytochrome P-450 CYP1A2 Inducers | 1 | 2020 | 1 | 0.690 |
Why?
|
Risk Assessment | 7 | 2025 | 2036 | 0.680 |
Why?
|
Models, Statistical | 1 | 2022 | 307 | 0.670 |
Why?
|
Thromboembolism | 1 | 2020 | 72 | 0.670 |
Why?
|
Neoplasm Staging | 9 | 2025 | 485 | 0.660 |
Why?
|
Drug Administration Schedule | 8 | 2021 | 299 | 0.650 |
Why?
|
Immunophenotyping | 2 | 2018 | 193 | 0.630 |
Why?
|
Practice Patterns, Physicians' | 2 | 2024 | 707 | 0.630 |
Why?
|
Consensus | 8 | 2025 | 224 | 0.630 |
Why?
|
Karnofsky Performance Status | 1 | 2019 | 12 | 0.630 |
Why?
|
Skin Neoplasms | 2 | 2016 | 413 | 0.620 |
Why?
|
Induction Chemotherapy | 7 | 2023 | 41 | 0.620 |
Why?
|
Translocation, Genetic | 6 | 2025 | 68 | 0.620 |
Why?
|
Follow-Up Studies | 16 | 2025 | 2442 | 0.610 |
Why?
|
Immunomodulation | 1 | 2018 | 30 | 0.610 |
Why?
|
Gene Expression Profiling | 8 | 2025 | 761 | 0.580 |
Why?
|
Dental Prophylaxis | 1 | 2018 | 1 | 0.580 |
Why?
|
Kaplan-Meier Estimate | 8 | 2021 | 416 | 0.570 |
Why?
|
Clinical Trials, Phase III as Topic | 6 | 2025 | 41 | 0.570 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2017 | 95 | 0.560 |
Why?
|
Genomics | 6 | 2025 | 357 | 0.550 |
Why?
|
Signaling Lymphocytic Activation Molecule Family | 1 | 2017 | 5 | 0.550 |
Why?
|
Survival Analysis | 7 | 2020 | 575 | 0.550 |
Why?
|
Central Nervous System Neoplasms | 2 | 2016 | 39 | 0.550 |
Why?
|
Catheterization, Central Venous | 1 | 2018 | 86 | 0.540 |
Why?
|
Lymphoma, B-Cell | 3 | 2025 | 61 | 0.540 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2025 | 861 | 0.540 |
Why?
|
Bacteremia | 1 | 2018 | 94 | 0.530 |
Why?
|
Cancer Survivors | 1 | 2018 | 112 | 0.530 |
Why?
|
Infusions, Intravenous | 4 | 2021 | 173 | 0.530 |
Why?
|
Blood Transfusion | 1 | 2017 | 157 | 0.520 |
Why?
|
Ambulatory Care | 1 | 2019 | 310 | 0.520 |
Why?
|
United States | 12 | 2023 | 7700 | 0.520 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2016 | 34 | 0.520 |
Why?
|
Incidence | 7 | 2024 | 1359 | 0.520 |
Why?
|
Cell Proliferation | 2 | 2020 | 981 | 0.520 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2017 | 297 | 0.510 |
Why?
|
Disease Management | 6 | 2021 | 234 | 0.510 |
Why?
|
Myeloproliferative Disorders | 1 | 2016 | 15 | 0.510 |
Why?
|
Health Status | 1 | 2019 | 433 | 0.510 |
Why?
|
Skin Diseases, Infectious | 1 | 2016 | 12 | 0.510 |
Why?
|
Bone Marrow | 7 | 2023 | 178 | 0.510 |
Why?
|
Plasmacytoma | 3 | 2022 | 9 | 0.500 |
Why?
|
Molecular Targeted Therapy | 4 | 2020 | 129 | 0.500 |
Why?
|
Boron Compounds | 3 | 2024 | 20 | 0.460 |
Why?
|
Proportional Hazards Models | 8 | 2023 | 724 | 0.460 |
Why?
|
Prospective Studies | 13 | 2025 | 3248 | 0.460 |
Why?
|
Glycine | 3 | 2024 | 49 | 0.450 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2025 | 520 | 0.450 |
Why?
|
Biomarkers | 7 | 2022 | 1379 | 0.440 |
Why?
|
Combined Modality Therapy | 7 | 2021 | 365 | 0.440 |
Why?
|
Tumor Microenvironment | 5 | 2023 | 152 | 0.440 |
Why?
|
Remission Induction | 6 | 2025 | 146 | 0.440 |
Why?
|
Thrombocytopenia | 2 | 2025 | 52 | 0.440 |
Why?
|
Hepatitis C | 1 | 2016 | 151 | 0.430 |
Why?
|
Killer Cells, Natural | 3 | 2020 | 216 | 0.430 |
Why?
|
Neoplasms | 2 | 2018 | 1348 | 0.420 |
Why?
|
Serum Amyloid A Protein | 1 | 2013 | 7 | 0.420 |
Why?
|
Young Adult | 12 | 2025 | 4613 | 0.410 |
Why?
|
Leukemia | 1 | 2013 | 62 | 0.410 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2024 | 127 | 0.400 |
Why?
|
Standard of Care | 2 | 2023 | 27 | 0.400 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2023 | 25 | 0.390 |
Why?
|
Neoplasms, Plasma Cell | 2 | 2023 | 3 | 0.390 |
Why?
|
Soft Tissue Neoplasms | 1 | 2012 | 31 | 0.380 |
Why?
|
Myelodysplastic Syndromes | 1 | 2013 | 86 | 0.380 |
Why?
|
Hemophilia A | 1 | 2011 | 57 | 0.380 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2011 | 35 | 0.370 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 58 | 0.370 |
Why?
|
Bone Neoplasms | 1 | 2013 | 125 | 0.370 |
Why?
|
Frailty | 2 | 2025 | 130 | 0.370 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2020 | 168 | 0.370 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2021 | 84 | 0.360 |
Why?
|
Clinical Decision-Making | 3 | 2025 | 159 | 0.360 |
Why?
|
Risk Factors | 10 | 2024 | 5293 | 0.360 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 308 | 0.350 |
Why?
|
Benzodioxoles | 1 | 2010 | 13 | 0.350 |
Why?
|
Purines | 1 | 2010 | 42 | 0.350 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2023 | 15 | 0.350 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 3 | 2024 | 33 | 0.340 |
Why?
|
Lymphoma, T-Cell | 2 | 2025 | 24 | 0.340 |
Why?
|
Cytogenetic Analysis | 5 | 2022 | 25 | 0.340 |
Why?
|
Immunoglobulin Light-chain Amyloidosis | 2 | 2021 | 6 | 0.340 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2022 | 14 | 0.340 |
Why?
|
Positron Emission Tomography Computed Tomography | 3 | 2020 | 50 | 0.330 |
Why?
|
Magnetic Resonance Imaging | 7 | 2018 | 2142 | 0.330 |
Why?
|
DNA Copy Number Variations | 3 | 2024 | 69 | 0.330 |
Why?
|
Adolescent | 9 | 2025 | 6151 | 0.320 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2025 | 125 | 0.320 |
Why?
|
Europe | 2 | 2020 | 193 | 0.320 |
Why?
|
Stem Cell Transplantation | 3 | 2023 | 78 | 0.320 |
Why?
|
Healthcare Disparities | 2 | 2023 | 348 | 0.320 |
Why?
|
Benzoquinones | 1 | 2009 | 14 | 0.320 |
Why?
|
Liver Neoplasms | 1 | 2012 | 294 | 0.320 |
Why?
|
Lactams, Macrocyclic | 1 | 2009 | 25 | 0.310 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2024 | 729 | 0.300 |
Why?
|
Boronic Acids | 3 | 2013 | 28 | 0.290 |
Why?
|
Pyrazines | 3 | 2013 | 34 | 0.290 |
Why?
|
Neutropenia | 3 | 2023 | 67 | 0.290 |
Why?
|
Chromosome Deletion | 2 | 2020 | 42 | 0.280 |
Why?
|
Bone Marrow Cells | 4 | 2022 | 237 | 0.280 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2020 | 213 | 0.270 |
Why?
|
Databases, Factual | 4 | 2020 | 850 | 0.270 |
Why?
|
Myeloablative Agonists | 3 | 2015 | 13 | 0.260 |
Why?
|
Diarrhea | 2 | 2024 | 76 | 0.260 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 2532 | 0.250 |
Why?
|
Adrenal Cortex Hormones | 2 | 2024 | 173 | 0.250 |
Why?
|
Antigens, CD19 | 1 | 2025 | 22 | 0.240 |
Why?
|
Immunity, Humoral | 1 | 2025 | 40 | 0.240 |
Why?
|
Chemoradiotherapy | 1 | 2025 | 65 | 0.240 |
Why?
|
Mutagenesis | 1 | 2025 | 130 | 0.240 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2024 | 287 | 0.230 |
Why?
|
Surveys and Questionnaires | 2 | 2024 | 2641 | 0.220 |
Why?
|
Whole Genome Sequencing | 4 | 2025 | 70 | 0.220 |
Why?
|
Chromatography, Liquid | 2 | 2021 | 130 | 0.220 |
Why?
|
Mutation | 4 | 2025 | 2571 | 0.220 |
Why?
|
Neoplasm Proteins | 2 | 2018 | 283 | 0.220 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2016 | 125 | 0.210 |
Why?
|
Models, Theoretical | 1 | 2025 | 271 | 0.210 |
Why?
|
Rituximab | 2 | 2015 | 83 | 0.210 |
Why?
|
CD47 Antigen | 1 | 2023 | 3 | 0.210 |
Why?
|
Meta-Analysis as Topic | 1 | 2023 | 78 | 0.210 |
Why?
|
Heterocyclic Compounds | 1 | 2022 | 12 | 0.200 |
Why?
|
Gene Deletion | 2 | 2024 | 303 | 0.200 |
Why?
|
Spain | 2 | 2020 | 33 | 0.200 |
Why?
|
Gene Dosage | 2 | 2021 | 64 | 0.200 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2025 | 303 | 0.200 |
Why?
|
Sex Factors | 2 | 2023 | 969 | 0.200 |
Why?
|
Graft vs Host Disease | 1 | 2023 | 110 | 0.200 |
Why?
|
Canada | 2 | 2020 | 154 | 0.200 |
Why?
|
Cell Cycle Proteins | 1 | 2025 | 396 | 0.200 |
Why?
|
Animals | 10 | 2024 | 20570 | 0.190 |
Why?
|
Workflow | 1 | 2022 | 68 | 0.190 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 1584 | 0.190 |
Why?
|
Biological Therapy | 1 | 2022 | 16 | 0.190 |
Why?
|
Artificial Intelligence | 1 | 2024 | 163 | 0.190 |
Why?
|
Leukemia, Plasma Cell | 1 | 2021 | 2 | 0.190 |
Why?
|
Software | 1 | 2025 | 381 | 0.190 |
Why?
|
Cell Line, Tumor | 5 | 2016 | 1451 | 0.190 |
Why?
|
Electrocardiography | 1 | 2024 | 549 | 0.180 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 671 | 0.180 |
Why?
|
Nutritional Status | 1 | 2022 | 98 | 0.180 |
Why?
|
Drug Administration Routes | 1 | 2021 | 21 | 0.180 |
Why?
|
Time Factors | 5 | 2020 | 3739 | 0.180 |
Why?
|
Population Surveillance | 2 | 2020 | 203 | 0.180 |
Why?
|
Retreatment | 2 | 2019 | 47 | 0.180 |
Why?
|
Immunoglobulin A | 1 | 2021 | 97 | 0.180 |
Why?
|
Genetic Loci | 1 | 2021 | 117 | 0.170 |
Why?
|
Administration, Cutaneous | 1 | 2020 | 31 | 0.170 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 189 | 0.170 |
Why?
|
Patient Dropouts | 1 | 2020 | 49 | 0.170 |
Why?
|
Denmark | 1 | 2020 | 17 | 0.170 |
Why?
|
Netherlands | 1 | 2020 | 24 | 0.170 |
Why?
|
Medical Oncology | 1 | 2021 | 66 | 0.170 |
Why?
|
Infusion Pumps | 1 | 2020 | 7 | 0.170 |
Why?
|
Sweden | 1 | 2020 | 56 | 0.170 |
Why?
|
Patient Satisfaction | 2 | 2021 | 431 | 0.170 |
Why?
|
Disease Susceptibility | 1 | 2020 | 166 | 0.170 |
Why?
|
Influenza, Human | 1 | 2022 | 206 | 0.170 |
Why?
|
Hemoglobins | 2 | 2018 | 135 | 0.170 |
Why?
|
Mass Spectrometry | 1 | 2021 | 304 | 0.160 |
Why?
|
Drug Compounding | 1 | 2020 | 75 | 0.160 |
Why?
|
Diagnostic Imaging | 2 | 2020 | 261 | 0.160 |
Why?
|
Prednisone | 1 | 2019 | 86 | 0.160 |
Why?
|
Thrombopoietin | 1 | 2019 | 11 | 0.160 |
Why?
|
Immunoglobulin G | 1 | 2021 | 462 | 0.160 |
Why?
|
Apoptosis | 3 | 2023 | 1066 | 0.160 |
Why?
|
Paraproteinemias | 1 | 2019 | 16 | 0.160 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 17 | 0.160 |
Why?
|
Diphenhydramine | 1 | 2019 | 9 | 0.160 |
Why?
|
Premedication | 1 | 2019 | 16 | 0.160 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2019 | 39 | 0.160 |
Why?
|
Transplantation, Haploidentical | 1 | 2018 | 4 | 0.160 |
Why?
|
Risk | 5 | 2021 | 373 | 0.160 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 147 | 0.160 |
Why?
|
Cystitis | 1 | 2018 | 10 | 0.150 |
Why?
|
Receptors, KIR | 1 | 2018 | 3 | 0.150 |
Why?
|
Stem Cells | 1 | 2021 | 259 | 0.150 |
Why?
|
Ibuprofen | 1 | 2018 | 18 | 0.150 |
Why?
|
Myeloid-Derived Suppressor Cells | 1 | 2018 | 7 | 0.150 |
Why?
|
B-Lymphocytes, Regulatory | 1 | 2018 | 5 | 0.150 |
Why?
|
Multimodal Imaging | 1 | 2019 | 66 | 0.150 |
Why?
|
Thoracic Vertebrae | 1 | 2018 | 33 | 0.150 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 536 | 0.150 |
Why?
|
Cell Count | 1 | 2018 | 130 | 0.150 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 26 | 0.150 |
Why?
|
Cytogenetics | 2 | 2016 | 9 | 0.150 |
Why?
|
Models, Biological | 2 | 2020 | 1180 | 0.150 |
Why?
|
Back Pain | 1 | 2018 | 50 | 0.150 |
Why?
|
Acetaminophen | 1 | 2019 | 59 | 0.150 |
Why?
|
Patient Safety | 1 | 2021 | 242 | 0.150 |
Why?
|
Precancerous Conditions | 2 | 2016 | 70 | 0.150 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2018 | 46 | 0.150 |
Why?
|
Periodontal Index | 1 | 2018 | 4 | 0.150 |
Why?
|
Drugs, Investigational | 1 | 2018 | 12 | 0.150 |
Why?
|
Pandemics | 1 | 2023 | 661 | 0.140 |
Why?
|
Receptors, IgG | 1 | 2018 | 37 | 0.140 |
Why?
|
Bone and Bones | 2 | 2016 | 142 | 0.140 |
Why?
|
Antibiotic Prophylaxis | 1 | 2018 | 54 | 0.140 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 78 | 0.140 |
Why?
|
Catheter-Related Infections | 1 | 2018 | 42 | 0.140 |
Why?
|
Glucocorticoids | 1 | 2019 | 188 | 0.140 |
Why?
|
Comorbidity | 1 | 2020 | 1117 | 0.140 |
Why?
|
Lumbar Vertebrae | 1 | 2018 | 142 | 0.140 |
Why?
|
Phagocytosis | 1 | 2018 | 264 | 0.140 |
Why?
|
Chronic Disease | 1 | 2020 | 748 | 0.130 |
Why?
|
Hemorrhage | 1 | 2018 | 266 | 0.130 |
Why?
|
B-Lymphocytes | 1 | 2020 | 569 | 0.130 |
Why?
|
Feasibility Studies | 1 | 2019 | 562 | 0.130 |
Why?
|
Gene Expression | 1 | 2020 | 836 | 0.130 |
Why?
|
Odds Ratio | 1 | 2018 | 768 | 0.130 |
Why?
|
Cohort Studies | 3 | 2019 | 2530 | 0.130 |
Why?
|
Zonula Occludens-1 Protein | 1 | 2016 | 7 | 0.130 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 46 | 0.130 |
Why?
|
Janus Kinase 1 | 1 | 2016 | 11 | 0.130 |
Why?
|
Pneumonia | 1 | 2019 | 286 | 0.130 |
Why?
|
Schnitzler Syndrome | 1 | 2016 | 1 | 0.130 |
Why?
|
Scleromyxedema | 1 | 2016 | 1 | 0.130 |
Why?
|
POEMS Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
|
Cryoglobulinemia | 1 | 2016 | 3 | 0.130 |
Why?
|
Xanthomatosis | 1 | 2016 | 8 | 0.130 |
Why?
|
Osteoclasts | 2 | 2013 | 48 | 0.130 |
Why?
|
Radiopharmaceuticals | 2 | 2017 | 186 | 0.130 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 712 | 0.130 |
Why?
|
Phenotype | 1 | 2020 | 1190 | 0.130 |
Why?
|
STAT3 Transcription Factor | 1 | 2016 | 70 | 0.120 |
Why?
|
Biomarkers, Pharmacological | 2 | 2012 | 6 | 0.120 |
Why?
|
ErbB Receptors | 1 | 2016 | 114 | 0.120 |
Why?
|
Lymphoma, Follicular | 1 | 2015 | 16 | 0.120 |
Why?
|
Bone Marrow Transplantation | 1 | 2015 | 139 | 0.120 |
Why?
|
Immunoglobulin Heavy Chains | 2 | 2025 | 46 | 0.120 |
Why?
|
Bone Remodeling | 1 | 2015 | 25 | 0.120 |
Why?
|
Mice | 5 | 2024 | 10800 | 0.120 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 101 | 0.120 |
Why?
|
Genetic Markers | 1 | 2015 | 126 | 0.110 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2014 | 36 | 0.110 |
Why?
|
Medicare | 1 | 2019 | 614 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2014 | 67 | 0.110 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2014 | 24 | 0.110 |
Why?
|
Antigens, CD34 | 1 | 2013 | 56 | 0.110 |
Why?
|
Unfolded Protein Response | 2 | 2013 | 56 | 0.110 |
Why?
|
Cerebrospinal Fluid | 1 | 2013 | 23 | 0.110 |
Why?
|
Administration, Metronomic | 1 | 2013 | 2 | 0.110 |
Why?
|
Cell Separation | 1 | 2013 | 147 | 0.110 |
Why?
|
Radiography | 2 | 2012 | 533 | 0.110 |
Why?
|
Castleman Disease | 1 | 2013 | 4 | 0.110 |
Why?
|
Transplantation, Homologous | 3 | 2022 | 244 | 0.110 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 5 | 0.100 |
Why?
|
Angiogenesis Inhibitors | 1 | 2014 | 77 | 0.100 |
Why?
|
beta Catenin | 1 | 2013 | 93 | 0.100 |
Why?
|
Osteolysis | 1 | 2013 | 17 | 0.100 |
Why?
|
Bone Diseases | 1 | 2013 | 22 | 0.100 |
Why?
|
Piperidines | 3 | 2020 | 63 | 0.100 |
Why?
|
Signal Transduction | 5 | 2016 | 3019 | 0.100 |
Why?
|
Cell Cycle | 2 | 2013 | 392 | 0.100 |
Why?
|
Mice, SCID | 4 | 2016 | 519 | 0.100 |
Why?
|
Myelolipoma | 1 | 2012 | 1 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2013 | 95 | 0.100 |
Why?
|
Genome, Human | 2 | 2025 | 233 | 0.100 |
Why?
|
Receptors, Glucocorticoid | 1 | 2012 | 27 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2024 | 1247 | 0.100 |
Why?
|
Hemarthrosis | 1 | 2011 | 3 | 0.100 |
Why?
|
Severity of Illness Index | 2 | 2020 | 1540 | 0.100 |
Why?
|
Factor VIII | 1 | 2011 | 32 | 0.100 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2022 | 41 | 0.090 |
Why?
|
Blood Coagulation Factors | 1 | 2011 | 16 | 0.090 |
Why?
|
Pericardial Effusion | 1 | 2011 | 21 | 0.090 |
Why?
|
Hydrazines | 2 | 2022 | 10 | 0.090 |
Why?
|
Vaccination | 2 | 2025 | 353 | 0.090 |
Why?
|
Epigenesis, Genetic | 1 | 2015 | 382 | 0.090 |
Why?
|
Triazoles | 2 | 2022 | 56 | 0.090 |
Why?
|
Acute Disease | 1 | 2013 | 670 | 0.090 |
Why?
|
Cell Movement | 1 | 2013 | 445 | 0.090 |
Why?
|
Autoantibodies | 1 | 2011 | 182 | 0.090 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 97 | 0.090 |
Why?
|
Heart Failure | 1 | 2018 | 899 | 0.090 |
Why?
|
Body Weight | 2 | 2023 | 377 | 0.090 |
Why?
|
G1 Phase | 1 | 2010 | 56 | 0.090 |
Why?
|
Multivariate Analysis | 1 | 2013 | 928 | 0.090 |
Why?
|
S Phase | 1 | 2010 | 78 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 463 | 0.080 |
Why?
|
Multicenter Studies as Topic | 2 | 2021 | 137 | 0.080 |
Why?
|
Pain | 2 | 2023 | 406 | 0.080 |
Why?
|
Diet | 2 | 2024 | 522 | 0.080 |
Why?
|
Cyclophosphamide | 2 | 2021 | 79 | 0.080 |
Why?
|
Fatigue | 2 | 2022 | 112 | 0.080 |
Why?
|
Metabolic Clearance Rate | 2 | 2020 | 49 | 0.080 |
Why?
|
International Agencies | 2 | 2019 | 7 | 0.080 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2009 | 82 | 0.080 |
Why?
|
Cell Differentiation | 4 | 2018 | 1346 | 0.080 |
Why?
|
Adenine | 2 | 2020 | 50 | 0.080 |
Why?
|
Cytokines | 1 | 2013 | 933 | 0.080 |
Why?
|
Pyrazoles | 2 | 2020 | 78 | 0.070 |
Why?
|
Nausea | 1 | 2009 | 112 | 0.070 |
Why?
|
Pyrimidines | 2 | 2020 | 135 | 0.070 |
Why?
|
Vomiting | 1 | 2009 | 138 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2025 | 641 | 0.070 |
Why?
|
Algorithms | 2 | 2025 | 1003 | 0.070 |
Why?
|
Body Mass Index | 2 | 2023 | 861 | 0.070 |
Why?
|
Doxorubicin | 2 | 2021 | 99 | 0.070 |
Why?
|
Cisplatin | 2 | 2021 | 139 | 0.070 |
Why?
|
Thymus Hyperplasia | 1 | 2006 | 2 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2006 | 85 | 0.060 |
Why?
|
HIV Infections | 1 | 2013 | 962 | 0.060 |
Why?
|
Trisomy | 1 | 2025 | 21 | 0.060 |
Why?
|
Brain | 1 | 2013 | 1549 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2025 | 122 | 0.060 |
Why?
|
Lentivirus | 1 | 2025 | 66 | 0.060 |
Why?
|
Genes, Tumor Suppressor | 1 | 2024 | 72 | 0.060 |
Why?
|
Sweetening Agents | 1 | 2024 | 21 | 0.050 |
Why?
|
Protein Interaction Maps | 1 | 2023 | 35 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2025 | 206 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 37 | 0.050 |
Why?
|
Diet, Vegetarian | 1 | 2022 | 3 | 0.050 |
Why?
|
Nutrition Surveys | 1 | 2024 | 142 | 0.050 |
Why?
|
Germinal Center | 1 | 2023 | 40 | 0.050 |
Why?
|
Proteinuria | 1 | 2023 | 41 | 0.050 |
Why?
|
Butyrates | 1 | 2022 | 16 | 0.050 |
Why?
|
Immunoglobulins | 1 | 2023 | 77 | 0.050 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2023 | 204 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2024 | 266 | 0.050 |
Why?
|
Drug Combinations | 1 | 2022 | 152 | 0.050 |
Why?
|
Single-Chain Antibodies | 1 | 2021 | 7 | 0.050 |
Why?
|
Diterpenes | 1 | 2021 | 21 | 0.050 |
Why?
|
Filgrastim | 1 | 2021 | 7 | 0.050 |
Why?
|
Etoposide | 1 | 2021 | 33 | 0.050 |
Why?
|
Taiwan | 1 | 2021 | 10 | 0.050 |
Why?
|
RNA Interference | 2 | 2016 | 618 | 0.050 |
Why?
|
Neurotoxicity Syndromes | 1 | 2021 | 21 | 0.050 |
Why?
|
Japan | 1 | 2021 | 59 | 0.040 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2020 | 9 | 0.040 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2020 | 10 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2023 | 888 | 0.040 |
Why?
|
Up-Regulation | 2 | 2013 | 375 | 0.040 |
Why?
|
Lymphoproliferative Disorders | 1 | 2021 | 39 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2020 | 39 | 0.040 |
Why?
|
Cost Savings | 1 | 2021 | 54 | 0.040 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 52 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2024 | 1108 | 0.040 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 15 | 0.040 |
Why?
|
Benchmarking | 1 | 2021 | 132 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2020 | 156 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2020 | 32 | 0.040 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 206 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2020 | 53 | 0.040 |
Why?
|
Kidney | 1 | 2023 | 444 | 0.040 |
Why?
|
Republic of Korea | 1 | 2021 | 163 | 0.040 |
Why?
|
ROC Curve | 1 | 2020 | 277 | 0.040 |
Why?
|
Reference Values | 1 | 2020 | 335 | 0.040 |
Why?
|
Prevalence | 1 | 2024 | 1346 | 0.040 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2019 | 8 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2023 | 428 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 288 | 0.040 |
Why?
|
Jehovah's Witnesses | 1 | 2019 | 18 | 0.040 |
Why?
|
Pain Measurement | 1 | 2020 | 339 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 40 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2023 | 476 | 0.040 |
Why?
|
Global Health | 1 | 2020 | 182 | 0.040 |
Why?
|
Basophils | 1 | 2018 | 14 | 0.040 |
Why?
|
Health Care Costs | 1 | 2021 | 210 | 0.040 |
Why?
|
Granzymes | 1 | 2018 | 21 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2018 | 109 | 0.040 |
Why?
|
Drug Approval | 1 | 2018 | 26 | 0.040 |
Why?
|
Myocarditis | 1 | 2019 | 67 | 0.040 |
Why?
|
Autografts | 1 | 2017 | 9 | 0.040 |
Why?
|
Hematology | 1 | 2017 | 12 | 0.040 |
Why?
|
Allografts | 1 | 2017 | 46 | 0.040 |
Why?
|
Education | 1 | 2017 | 69 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2006 | 1189 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2018 | 189 | 0.030 |
Why?
|
RNA, Small Interfering | 2 | 2013 | 898 | 0.030 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2016 | 28 | 0.030 |
Why?
|
Erlotinib Hydrochloride | 1 | 2016 | 20 | 0.030 |
Why?
|
Atrial Fibrillation | 1 | 2024 | 833 | 0.030 |
Why?
|
Radiotherapy | 1 | 2016 | 64 | 0.030 |
Why?
|
Research Design | 1 | 2019 | 572 | 0.030 |
Why?
|
Genetic Testing | 1 | 2016 | 131 | 0.030 |
Why?
|
Cysteine Endopeptidases | 1 | 2016 | 94 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2020 | 1637 | 0.030 |
Why?
|
Cause of Death | 1 | 2016 | 220 | 0.030 |
Why?
|
Child | 1 | 2025 | 4431 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 189 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2015 | 87 | 0.030 |
Why?
|
Societies, Medical | 1 | 2017 | 363 | 0.030 |
Why?
|
Hospitalization | 1 | 2022 | 1338 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 544 | 0.030 |
Why?
|
Blotting, Western | 1 | 2016 | 610 | 0.030 |
Why?
|
Survivors | 1 | 2015 | 169 | 0.030 |
Why?
|
Karyotype | 1 | 2014 | 18 | 0.030 |
Why?
|
Interspersed Repetitive Sequences | 1 | 2014 | 13 | 0.030 |
Why?
|
Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2013 | 2 | 0.030 |
Why?
|
Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2013 | 3 | 0.030 |
Why?
|
Syndecan-1 | 1 | 2013 | 9 | 0.030 |
Why?
|
Regulatory Factor X Transcription Factors | 1 | 2013 | 15 | 0.030 |
Why?
|
X-Box Binding Protein 1 | 1 | 2013 | 13 | 0.030 |
Why?
|
Receptors, LDL | 1 | 2013 | 34 | 0.030 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2013 | 39 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 165 | 0.030 |
Why?
|
Chemokine CXCL12 | 1 | 2013 | 17 | 0.030 |
Why?
|
Nicotinamide Mononucleotide | 1 | 2013 | 2 | 0.030 |
Why?
|
Acrylamides | 1 | 2013 | 15 | 0.030 |
Why?
|
Enzyme Induction | 1 | 2013 | 45 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2013 | 36 | 0.030 |
Why?
|
Wnt Proteins | 1 | 2013 | 98 | 0.030 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2013 | 32 | 0.030 |
Why?
|
Niacinamide | 1 | 2013 | 33 | 0.030 |
Why?
|
Transplantation, Heterologous | 1 | 2013 | 229 | 0.030 |
Why?
|
Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 18 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2013 | 97 | 0.030 |
Why?
|
Sirtuin 1 | 1 | 2013 | 27 | 0.030 |
Why?
|
Amides | 1 | 2013 | 56 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 93 | 0.030 |
Why?
|
Nitriles | 1 | 2013 | 69 | 0.030 |
Why?
|
Wnt Signaling Pathway | 1 | 2013 | 81 | 0.030 |
Why?
|
NAD | 1 | 2013 | 53 | 0.020 |
Why?
|
Age Factors | 1 | 2016 | 1553 | 0.020 |
Why?
|
Endoplasmic Reticulum | 1 | 2013 | 173 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2013 | 201 | 0.020 |
Why?
|
Rabbits | 1 | 2013 | 332 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 198 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2013 | 454 | 0.020 |
Why?
|
Viral Load | 1 | 2013 | 229 | 0.020 |
Why?
|
Cell Survival | 1 | 2013 | 573 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2011 | 24 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2013 | 346 | 0.020 |
Why?
|
Pharmacogenetics | 1 | 2011 | 27 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 373 | 0.020 |
Why?
|
NF-kappa B | 1 | 2013 | 469 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2013 | 1271 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2013 | 2154 | 0.020 |
Why?
|
Cell Line | 1 | 2013 | 2038 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2011 | 432 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 1183 | 0.020 |
Why?
|
Transcription Factors | 1 | 2013 | 1506 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2006 | 963 | 0.010 |
Why?
|